Related Experiment Videos
Electrophysiologic effects of amrinone
The American Journal of Cardiology
|July 22, 1985
Summary
Amrinone, a drug for congestive heart failure (CHF), was studied for its effects on heart rhythms. It improved atrioventricular (AV) conduction and did not significantly increase dangerous ventricular arrhythmias in CHF patients.
Area of Science:
- Cardiology
- Clinical Electrophysiology
- Pharmacology
Background:
- Congestive heart failure (CHF) patients often experience complex ventricular arrhythmias.
- Evaluating the electrophysiologic safety of new CHF treatments is crucial for this patient group.
Purpose of the Study:
- To assess the electrophysiologic effects of intravenous amrinone in patients with CHF.
- To determine the safety and potential arrhythmogenic risks of amrinone in this population.
Main Methods:
- Fifteen patients (NYHA class II-IV CHF) underwent hemodynamic and electrophysiologic testing.
- Amrinone was administered intravenously (10-20 micrograms/kg/min), with prior cessation of all cardioactive drugs.
- Holter monitoring was conducted during acute oral amrinone administration in 10 patients.
Main Results:
- Amrinone reduced atrial effective refractory period (256 to 240 ms) and AV nodal functional refractory period (374 to 356 ms).
- Enhanced maximal 1:1 AV nodal conduction was observed (371 to 334 ms).
- No significant changes in ventricular extrasystoles or tachycardia frequency were noted; ventricular couple frequency slightly increased.
Conclusions:
- Amrinone enhances atrioventricular (AV) conduction in CHF patients.
- Acute administration of amrinone does not appear to pose significant arrhythmogenic potential in this population.